{"protocolSection": {"identificationModule": {"nctId": "NCT04051710", "orgStudyIdInfo": {"id": "CR176-17"}, "organization": {"fullName": "Aurobindo Pharma Ltd", "class": "INDUSTRY"}, "briefTitle": "Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH", "officialTitle": "Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate Efficacy and Safety of Beclomethasone Dipropionate Metered Dose Inhaler (Inhalation Aerosol) (0.04mg/ INH) in Male and/ or Female Subjects With Asthma", "acronym": "QVR"}, "statusModule": {"statusVerifiedDate": "2020-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-03-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-08-29", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-12-20", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-08-05", "studyFirstSubmitQcDate": "2019-08-08", "studyFirstPostDateStruct": {"date": "2019-08-09", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-10-22", "resultsFirstSubmitQcDate": "2020-10-22", "resultsFirstPostDateStruct": {"date": "2020-11-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-10-22", "lastUpdatePostDateStruct": {"date": "2020-11-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Aurobindo Pharma Ltd", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "To compare the therapeutic equivalence of Beclomethasone Dipropionate MDI (Inhalation Aerosol) 0.04 mg/ INH with the marketed QVAR\u00ae 40 mcg (Beclomethasone dipropionate hydrofluoroalkane (HFA)) and to demonstrate superiority of both active treatments over placebo.", "detailedDescription": "This study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in terms of improvement in FEV1 measured before and after 4 weeks of treatment in adult patients with chronic stable asthma."}, "conditionsModule": {"conditions": ["Bronchial Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1550, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group-I (Test)", "type": "EXPERIMENTAL", "description": "One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.", "interventionNames": ["Drug: Test Product"]}, {"label": "Group-II (Reference)", "type": "ACTIVE_COMPARATOR", "description": "One inhalation of QVAR\u00ae 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.", "interventionNames": ["Drug: Reference Product"]}, {"label": "Group-III (Placebo)", "type": "PLACEBO_COMPARATOR", "description": "One inhalation of Placebo Inhalation Aerosol twice daily.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Test Product", "description": "Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg", "armGroupLabels": ["Group-I (Test)"], "otherNames": ["Test"]}, {"type": "DRUG", "name": "Reference Product", "description": "Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg", "armGroupLabels": ["Group-II (Reference)"], "otherNames": ["QVAR"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo Product", "armGroupLabels": ["Group-III (Placebo)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in FEV1 From Pre Dose to End of Treatment", "description": "Mean change in Forced Expiratory volume in 1 second (FEV 1) from baseline to end of study visit", "timeFrame": "4 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Adult male or female subjects of non-childbearing or of childbearing potential committing to consistent and correct use of an acceptable method of birth control.\n2. Diagnosis of asthma as defined by the National Asthma Education and Prevention Program at least 12 months prior to screening.\n3. Pre-bronchodilator FEV1 of \\>45% and \\<85% of predicted value during the screening visit and on the first day of treatment.\n4. \\>15% and \\>0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI).\n5. Patients should be stable on their chronic asthma treatment regimen for at least four weeks prior to enrollment.\n6. Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had \\<10 pack-years of historical use.\n7. Ability to replace current short-acting \u03b2 agonist (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study. Subjects should be able to withhold all inhaled SABAs for at least six hours prior to lung function assessments on study visits.\n8. Ability to discontinue their asthma medications (inhaled corticosteroids and long-acting \u03b2 agonists) during the run-in period and for remainder of the study.\n9. Willingness to give their written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year prior to the screening or during the run-in period.\n2. Significant respiratory disease other than asthma (COPD, interstitial lung disease, etc.)\n3. Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.\n4. Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within four weeks prior to the screening, during the run-in period, or on the day of treatment.\n5. Hypersensitivity to any sympathomimetic drug (e.g., albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.\n6. Patients receiving \u03b22-blockers, anti-arrhythmics, anti-depressants, and monoamine oxidase inhibitors within 4 weeks prior to the screening.\n7. Patients who required systemic corticosteroids (for any reason) within the past 2 months.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Joseph Marialouis", "affiliation": "Aurobindo Pharma USA Inc", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Maharashtra Medical Foundation Joshi Hospital", "city": "Pune", "state": "Maharashtra", "zip": "411004", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Not decided"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Group I (Test)", "description": "One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.\n\nTest Product: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg"}, {"id": "FG001", "title": "Group II", "description": "One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Reference) twice daily.\n\nReference Product: QVAR\u00ae Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg"}, {"id": "FG002", "title": "Group III (Placebo)", "description": "One inhalation of Placebo inhalation aerosol twice daily."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "620"}, {"groupId": "FG001", "numSubjects": "620"}, {"groupId": "FG002", "numSubjects": "310"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "616"}, {"groupId": "FG001", "numSubjects": "612"}, {"groupId": "FG002", "numSubjects": "306"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Test Group", "description": "Subjects randomly enrolled into test group received test comparator, Beclomethasone dipropinate, 0.04 mg/INH to administer one inhalation twice daily"}, {"id": "BG001", "title": "Reference Group", "description": "Subjects randomly enrolled into Reference group received Reference comparator, QVAR\u00ae containing Beclomethasone dipropinate, 0.04 mg/INH to administer one inhalation twice daily"}, {"id": "BG002", "title": "Placebo Group", "description": "Subjects randomly enrolled into Placebo group received a Placebo device to administer one inhalation twice daily"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "617"}, {"groupId": "BG001", "value": "615"}, {"groupId": "BG002", "value": "308"}, {"groupId": "BG003", "value": "1540"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41", "spread": "12.71"}, {"groupId": "BG001", "value": "41.8", "spread": "12.85"}, {"groupId": "BG002", "value": "40.6", "spread": "12.86"}, {"groupId": "BG003", "value": "41.2", "spread": "12.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "267"}, {"groupId": "BG001", "value": "272"}, {"groupId": "BG002", "value": "139"}, {"groupId": "BG003", "value": "678"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "350"}, {"groupId": "BG001", "value": "343"}, {"groupId": "BG002", "value": "169"}, {"groupId": "BG003", "value": "862"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "617"}, {"groupId": "BG001", "value": "615"}, {"groupId": "BG002", "value": "308"}, {"groupId": "BG003", "value": "1540"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "India", "categories": [{"measurements": [{"groupId": "BG000", "value": "617"}, {"groupId": "BG001", "value": "615"}, {"groupId": "BG002", "value": "308"}, {"groupId": "BG003", "value": "1540"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in FEV1 From Pre Dose to End of Treatment", "description": "Mean change in Forced Expiratory volume in 1 second (FEV 1) from baseline to end of study visit", "populationDescription": "Mean change of FEV1 from baseline to end of study was measured", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litres", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Group-I (Test)", "description": "One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.\n\nTest Product: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg"}, {"id": "OG001", "title": "Group-II (Reference)", "description": "One inhalation of QVAR\u00ae 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.\n\nReference Product: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg"}, {"id": "OG002", "title": "Group-III (Placebo)", "description": "One inhalation of Placebo Inhalation Aerosol twice daily.\n\nPlacebo: Placebo Product"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "577"}, {"groupId": "OG001", "value": "566"}, {"groupId": "OG002", "value": "282"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.23", "spread": "0.01"}, {"groupId": "OG001", "value": "0.22", "spread": "0.01"}, {"groupId": "OG002", "value": "0.09", "spread": "0.01"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.1", "timeFrame": "1 year", "eventGroups": [{"id": "EG000", "title": "Group I (Test)", "description": "One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.\n\nTest Product: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg", "deathsNumAffected": 0, "deathsNumAtRisk": 619, "seriousNumAffected": 0, "seriousNumAtRisk": 619, "otherNumAffected": 39, "otherNumAtRisk": 619}, {"id": "EG001", "title": "Group II (Reference)", "description": "One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Reference) twice daily.\n\nReference Product: QVAR\u00ae Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg", "deathsNumAffected": 0, "deathsNumAtRisk": 620, "seriousNumAffected": 0, "seriousNumAtRisk": 620, "otherNumAffected": 25, "otherNumAtRisk": 620}, {"id": "EG002", "title": "Group III (Placebo)", "description": "One inhalation of Placebo inhalation aerosol twice daily.", "deathsNumAffected": 0, "deathsNumAtRisk": 310, "seriousNumAffected": 0, "seriousNumAtRisk": 310, "otherNumAffected": 18, "otherNumAtRisk": 310}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Headache", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 310}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Vertigo", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 310}]}, {"term": "Leukocytosis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 310}]}, {"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 310}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 310}]}, {"term": "Hyperchlorhydria", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 310}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Inflammation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 310}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 310}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 310}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Migraine", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}, {"term": "Alanine Aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 310}]}, {"term": "Aspartate Aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 310}]}, {"term": "Alkaline phosphatase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 310}]}, {"term": "white blood cells decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 619}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 620}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 310}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the ownership of all the data generated from the study and PI has no rights to publish the results or any information derived from the study."}, "pointOfContact": {"title": "Dr. Joseph Marialouis", "organization": "Aurobindo Pharma", "email": "jmarialouis@aurobindousa.com", "phone": "9196150585", "phoneExt": "4013"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-08-07", "uploadDate": "2020-10-15T12:03", "filename": "Prot_000.pdf", "size": 2003079}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-10-23", "uploadDate": "2020-10-15T12:05", "filename": "SAP_001.pdf", "size": 537504}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Bronchial Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M4800", "name": "Beclomethasone", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}